Loading...
•
Jun 30, 2020
Personalis Q2 2020 Earnings Report
Reported record revenues with strong execution across population sequencing and biopharma businesses.
Key Takeaways
Personalis reported record revenues of $19.5 million for the second quarter of 2020, a 23% increase compared to $15.8 million in the same period of the prior year. The VA MVP accounted for $14.8 million of total revenues, while biopharmaceutical and other customers contributed $4.7 million.
Reported record revenues of $19.5 million, a 23% increase year-over-year.
32 customers have placed orders for NeXT as of June 30, 2020, with 6 new customers in Q2 2020.
Announced collaborations with Sarepta Therapeutics and Berry Genomics.
Completed the 75,000th whole human genome sequenced under the VA MVP contract.
Forward Guidance
Due to continued uncertainty surrounding the COVID-19 pandemic, Personalis will not provide an outlook for fiscal 2020 at this time and will plan to give an update during its third quarter earnings announcement and press release, to the extent practicable, based on available information at that time.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...